A Radomized Clinical Trial on the Clinical Efficacy and Toxicities of Single-agent Paclitaxel Liposome versus Paclitaxel Liposome plus Oxaliplatin as First-line 
Chemotherapy for Advanced Non-small Cell Lung Cancer in Elderly Patients

A Radomized Clinical Trial on the Clinical Efficacy and Toxicities of Single-agent Paclitaxel Liposome versus Paclitaxel Liposome plus Oxaliplatin as First-line 
Chemotherapy for Advanced Non-small Cell Lung Cancer in Elderly Patients

Background and objective The third generation single-agent drug has been recommended as a first-line chemotherapy for elderly patients with advanced non-small cell lung cancer (NSCLC). The aim of the current radomized trial is to compare the clinical efficacy and toxicities of single-agent paclitaxe...

Full description

Bibliographic Details
Main Authors: Xiaomei ZENG, Zhixi LI, Mei HOU
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2012-02-01
Series:Chinese Journal of Lung Cancer
Subjects:
Paclitaxel liposome
Oxaliplatin
Lung neoplasms
Aged
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2012.02.04

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2012.02.04

Similar Items